

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Clover Biopharmaceuticals, Ltd.**

**三葉草生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2197)**

**POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON MAY 27, 2022**

The Board announces that the resolutions numbered 1 to 5 and 7 as set out in the Notice were duly passed by the Shareholders by way of poll at the Annual General Meeting, and the resolution numbered 6 as set out in the Notice was duly passed by independent Shareholders by way of poll at the Annual General Meeting.

The board of directors (the “**Board**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**”) is pleased to announce the poll results of the annual general meeting of the Company (the “**Annual General Meeting**”) held at Room 1102, Building 1, Chinese Financial Center, No. 33, Jiaozhi Street, High-tech Zone, Chengdu, Sichuan province, PRC on Friday, May 27, 2022 at 10:00 a.m..

Reference is made to the Company’s circular (the “**Circular**”) in connection with the Annual General Meeting and notice of the Annual General Meeting (the “**Notice**”) dated April 22, 2022. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The poll results in respect of the resolutions proposed at the Annual General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2021.	616,397,988 (100.000000%)	0 (0.000000%)
2.	To re-elect the following persons:		
(a)	Dr. WU Xiaobin, independent non-executive director of the Company	585,714,054 (99.995390%)	27,000 (0.004610%)
(b)	Mr. Jeffrey FARROW, independent non-executive director of the Company	515,737,988 (88.048803%)	70,003,066 (11.951197%)
(c)	Mr. Thomas LEGGETT, independent non-executive director of the Company	515,710,988 (88.044194%)	70,030,066 (11.955806%)
3.	To authorise the board of directors of the Company to fix the remuneration of the directors.	616,397,988 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
4.	To re-appoint Ernst & Young as auditor of the Company and authorise the board of directors of the Company to fix their remuneration.	616,397,988 (100.000000%)	0 (0.000000%)
5.	(A) To give a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company as at the date of this resolution.	467,448,320 (80.421878%)	113,796,900 (19.578122%)
	(B) To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued share capital of the Company as at the date of this resolution.	581,245,220 (100.000000%)	0 (0.000000%)
	(C) To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 5(A) to issue shares by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 5(B).	467,448,320 (80.421878%)	113,796,900 (19.578122%)
6.	THAT the grant of share options (the “ <b>Share Options</b> ”) to Mr. LIANG Joshua G (“ <b>Mr. LIANG</b> ”), the executive director and substantial shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company, to subscribe for 9,031,000 ordinary shares of US\$0.0001 each in the share capital of the Company (the “ <b>Shares</b> ”) at an exercise price of HK\$7.3 per Share under the post-IPO share option plan of the Company adopted by the Company on September 26, 2021 (the “ <b>Post-IPO Share Option Plan</b> ”) and otherwise on such terms as stipulated in the offer letter to be issued by the Company pursuant to the Post-IPO Share Option Plan be and is hereby approved and THAT the board of directors of the Company be and is hereby authorised to exercise all rights and powers available to it as it may in its sole discretion consider necessary or expedient to give full effect to the grant of the Share Options to Mr. LIANG and the issue of the Shares upon the exercise of the Share Options by Mr. LIANG.	222,841,220 (68.832281%)	100,904,000 (31.167719%)
Special Resolution		Number of Votes (%)	
		For	Against
7.	THAT the proposed amendments to the articles of association of the Company as set out in the circular of the Company dated April 22, 2022 (the “ <b>Proposed Amendments</b> ”) be and is hereby approved and the directors of the Company be and are hereby authorised to deal with on behalf of the Company the relevant application(s), approval(s), registration(s), filing(s) and other related procedures or issues and to make further amendment(s) (where necessary) pursuant to the requirements of the relevant governmental and/or regulatory authorities arising from the Proposed Amendments.	581,245,220 (100.000000%)	0 (0.000000%)

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

As more than 50% the votes were cast in favour of each of the resolutions numbered 1 to 6 above, all such resolutions were duly passed as ordinary resolutions at the Annual General Meeting.

As not less than three-fourths of the votes were cast in favour of the resolution numbered 7 above, the said resolution was duly passed as a special resolution at the Annual General Meeting.

The total number of issued Shares as at the date of the Annual General Meeting was 1,160,821,723 Shares. As set out in the Circular, Mr. LIANG Joshua G, his associates and all Core Connected Persons of the Company must abstain from voting in favor of the resolution approving the Proposed Granting of the Options at the Annual General Meeting. Accordingly, Mr. LIANG Joshua G, his associates and all Core Connected Persons of the Company, who held in aggregate a total of 526,831,210 Shares representing approximately 45.38% of the total number of Shares in issue at the date of the Annual General Meeting, were required to and did abstain from voting on resolution numbered 6 at the Annual General Meeting.

Save as disclosed above, there were (i) no Shareholders being required under the Listing Rules to abstain from voting in respect of the resolutions at the Annual General Meeting and no Shareholders stating his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the Annual General Meeting, (ii) no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting, and (iii) no Shares entitling the holders to attend and abstain from voting in favour of any resolution at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. Accordingly, the total number of shares of the Company entitling the holder to attend and vote on the resolution(s) numbered 1 to 5 and 7 was 1,160,821,723 Shares, and the total number of shares of the Company entitling the holder to attend and vote on the resolution numbered 6 was 633,990,513 Shares as at the date of the Annual General Meeting.

All directors of the Company, namely Dr. Peng LIANG, Mr. Joshua G LIANG, Dr. Xiaodong WANG, Mr. Dong LYU, Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT attended the Annual General Meeting, either in person or by means of electronic facilities.

Computershare Hong Kong Investor Services Limited, the branch share registrar in Hong Kong of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

By order of the Board  
**Clover Biopharmaceuticals, Ltd.**  
**Dr. Peng LIANG**  
*Chairman of the Board*

Shanghai, PRC, May 27, 2022

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG and Mr. Dong LYU as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*